Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin with neoadjuvant chemoradiotherapy for rectal cancer downstaging
IRCT20170728035349N2Phase 3Completed
- Sponsor
- Zanjan University of Medical Sciences
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rectal cancer comparing Metformin plus neoadjuvant chemoradiotherapy with Placebo plus neoadjuvant chemoradiotherapy (2 arms). Primary endpoints: Tumor downstaging rate, Local recurrence probability and 3 more. Started Jan 2022; status: completed.
02
Drugs
metformin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on IRCT20170728035349N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170728035349N2.